On March 5, 2014, Pozen, Inc. (NASDAQ:POZN) reported financial results for the fourth quarter and full year ended December 31, 2013. Total revenues in the fourth quarter were $4.7 million, comprised of $1.7 million in royalties on roughly $25 million in sales of Vimovo at AstraZeneca (NYSE:AZN) and $3.0 million in licensing revenue relating to amortization of the $15 million upfront payment from Sanofi U.S. on the PA licensing agreement in September 2013. Revenues for the fourth quarter were essentially dead-on with our forecast. Revenues for the full year 2013 totaled approximately $10.3 million, which included $6.3 million in royalties from roughly $91 million in worldwide sales of Vimovo at AstraZeneca and $4.0 million in amortized...
|FREE||SA PRO MEMBERS|
|IDEA GENERATOR||X||Exclusive access to 10 PRO ideas every day|
|INVESTING IDEAS LIBRARY||X||Exclusive access to PRO library of more than 15,000 ideas|
|SECTOR EXPERT NETWORK||X||Exclusive access to all sector experts for direct consultation|
|PERFORMANCE TRACKING||X||Track performance of all PRO stock ideas|
|PROFESSIONAL TOOLS||X||Professional Idea Filters to zero-in based on industry, market cap and more|